新型生物假体静脉瓣VenoValve首次人体试验:慢性静脉功能不全患者早期结果
本文报告了首个人体试验,将新型假体静脉瓣VenoValve手术植入10例血栓后综合征所致C5-C6慢性静脉功能不全患者的股静脉。技术成功率为100%,4例发生不良事件,1例瓣膜血栓形成。达到6个月随访的5例患者静脉临床严重程度评分降低61%、疼痛视觉模拟评分降低57%、反流时间减少40%,VEINES-QOL/Sym问卷有统计学显著改善。
要点
- VenoValve股静脉植入技术成功率达100%,早期安全性可接受
- 6个月随访时静脉临床严重程度评分降低61%、疼痛评分降低57%
- 反流时间减少40%,生活质量问卷有统计学显著改善
核心结论
- VenoValve首次人体试验早期结果显示临床结局和生活质量改善,是首个在6个月随访中显示成功的假体静脉瓣。
研究设计与样本
- 首次人体研究,在哥伦比亚波哥大经当地伦理委员会和哥伦比亚国家食品药品监督局批准,将VenoValve手术植入10例血栓后综合征所致C5-C6慢性静脉功能不全患者的股静脉。
- 术后2天、14天及之后每30天随访至6个月,评估不良事件、反流时间、静脉临床严重程度评分、疼痛视觉模拟评分和VEINES-QOL/Sym问卷。
主要发现
- 10例患者均成功将VenoValve植入股静脉,为门诊手术,技术成功率100%;9例在区域麻醉下、1例在局部麻醉下完成,6例需要牛心包补片静脉成形术。
- 共发生4例不良事件:1例切口部位血肿经抽吸处理,2例C6患者浅表伤口感染经抗生素治疗,1例华法林抗凝相关出血并发症。
- 1例患者因抗凝未达标于5个月时VenoValve血栓形成。
- 达到6个月随访的5例患者静脉临床严重程度评分较基线降低61%,疼痛视觉模拟评分降低57%,反流时间减少40%,VEINES-QOL/Sym问卷有统计学显著改善。
- 瓣膜闭塞患者除反流时间外所有领域均有改善,因其溃疡在血栓形成前已接近愈合。
临床怎么用
- VenoValve为深静脉系统慢性静脉功能不全提供了一种新的假体瓣膜治疗选择,早期结果显示可改善临床严重程度、疼痛、反流和生活质量。
- 术后需关注抗凝管理,抗凝未达标与瓣膜血栓形成相关。
局限性
- 样本量小(10例),仅5例达到6个月随访,结果需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic venous insufficiency (CVI) is a disease characterized by failure of the venous valves that allow blood from the lower limbs to return to the heart. The more severe types of CVI (C4b-C6 disease) significantly influence patients' quality of life (QOL). The treatment options for CVI of the deep system are limited. The present study is the first-in-human study using a prosthetic venous valve, VenoValve, to initially evaluate patient outcomes. We evaluated the feasibility, initial safety, and performance outcomes of the VenoValve. METHODS: Ten patients with C5-C6 CVI of the deep venous system secondary to postthrombotic syndrome had had a VenoValve surgically implanted into the femoral vein in Bogota, Colombia, under approval of the local ethics committee and Colombian National Food and Drug Surveillance Institute, national health care regulatory body, or the Colombian National Food and Drug Surveillance Agency. Follow-up examinations were conducted postoperatively at 2 and 14 days and then every 30 days for 6 months. The results of the assessments for adverse events, reflux time, disease severity (venous clinical severity scores), pain scores (visual analog scale), and QOL (VEINES-QOL/Sym [venous insufficiency epidemiological and economic study-QOL/symptoms] questionnaire) were documented. RESULTS: Ten patients underwent successful implantation of the VenoValve into the femoral vein as outpatients (100% technical success rate). Of the 10 patients, 9 had undergone VenoValve placement under regional anesthesia and 1 under local anesthesia. Six patients had required bovine patch angioplasty of the vein. Four adverse events occurred, including one case of hematoma at the incision site that was aspirated, 2 cases of superficial wound infection in C6 patients treated with antibiotics, and 1 case of a bleeding complication due to warfarin anticoagulation. One patient's VenoValve had thrombosed at 5 months due to nontherapeutic anticoagulation. Improvements in all 5 patients who had reached the 6-month follow-up mark with the VenoValve were demonstrated during the study period by decreases in the venous clinical severity scores (61% decrease from baseline), visual analog scale for pain scores (57% decrease), and reflux time (40% decrease) and a statistically significant improvement in the VEINES-QOL/Sym questionnaire. The patient with the occluded VenoValve had experienced improvements in all areas except for the reflux time. The latter patient had shown improvement because her ulcer had nearly healed before the occurrence of the thrombosis. CONCLUSIONS: The early results of the first-in-human trial using the VenoValve appear promising, with improvements in clinical outcomes and QOL. The VenoValve is the first prosthetic valve that has shown success at 6 months of follow-up. These findings offer insight for creating better outcomes for these highly disabled patients.
引用
- Ulloa JH, Glickman M. Human trial using the novel bioprosthetic VenoValve in patients with chronic venous insufficiency. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 33221526. doi:10.1016/j.jvsv.2020.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。